12 Health Care Stocks Moving In Friday's Pre-Market Session

Benzinga · 04/04 12:05
Gainers
- Impact BioMedical (AMEX:IBO) stock increased by 80.6% to $0.84 during Friday's pre-market session. The market value of their outstanding shares is at $9.6 million.
- Biodexa Pharmaceuticals (NASDAQ:BDRX) shares rose 25.15% to $1.84. The market value of their outstanding shares is at $1.2 million.
- Entero Therapeutics (NASDAQ:ENTO) stock moved upwards by 23.77% to $0.54. The market value of their outstanding shares is at $2.5 million.
- Sangamo Therapeutics (NASDAQ:SGMO) shares moved upwards by 23.73% to $0.77. The market value of their outstanding shares is at $173.0 million.
- Kairos Pharma (AMEX:KAPA) shares moved upwards by 14.89% to $1.08. The company's market cap stands at $14.7 million.
- ZyVersa Therapeutics (NASDAQ:ZVSA) stock moved upwards by 12.06% to $0.68. The company's market cap stands at $1.7 million.
Losers
- KORU Medical Systems (NASDAQ:KRMD) shares declined by 57.2% to $1.01 during Friday's pre-market session. The company's market cap stands at $46.4 million.
- NeuroOne Medical Tech (NASDAQ:NMTC) stock fell 41.28% to $0.51. The market value of their outstanding shares is at $15.5 million.
- XOMA Royalty (NASDAQ:XOMAP) shares decreased by 35.09% to $16.71.
- Nexalin Technology (NASDAQ:NXL) shares declined by 30.39% to $1.26. The market value of their outstanding shares is at $16.7 million.
- Dianthus Therapeutics (NASDAQ:DNTH) shares decreased by 23.34% to $13.01. The company's market cap stands at $417.9 million.
- Maze Therapeutics (NASDAQ:MAZE) stock fell 22.75% to $7.2. The market value of their outstanding shares is at $315.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.